VIENNA, April 2021: Biome Diagnostics GmbH is a global leader in microbiome diagnostics and specializes in the analysis and interpretation of the human intestinal microbiome. Currently, the Austrian company puts all efforts in the development of a diagnostic analysis for response/non-response to immune-checkpoint inhibitors (ICIs) based on the signature of the intestinal microbiome of individual patients. For the first time it will be possible for oncologists to predict the response and potential side effects of cancer immunotherapy before treatment start. At the same time the analysis will enable more patients to receive effective and safe immune checkpoint inhibitor therapy.
This groundbreaking project was recently submitted for funding to the Austrian Research Promotion Agency (FFG) as a General Programme. The FFG is the national funding agency for industrial research and development and aims to strengthen the competitiveness of companies based in Austria by funding the development of new products, processes and services.
The biomarker project has been thoroughly assessed in terms of technical, economic and innovative aspects and finally approved and granted funding from the FFG. This is yet another major milestone for Biome Diagnostics GmbH and an acknowledgement for their valuable contribution towards more effective cancer treatments.